Two biopharma IPOs in the US continue streak of (mostly) positive returns; two new European VC funds launch as Irish antibiotic developer raises $65m; and Halozyme, Ziopharm price offerings.
Two biopharmaceutical companies launched similar initial public offerings in the US within a day of each other – G1 Therapeutics Inc. on May 16 and argenx SE on May 17 – and raised more than $200m between the pair of them.
The recent biopharma IPO boom brings the 2017 total to 13 – a lucky number so far with few of the newly public drug developers' stocks trading under their offering...
Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.
The Italian drugmaker gets rights to Phase III-ready asset radiprodil.
GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.
New CEO Renée Aguiar-Lucander is marking her mark.
